Neurológia pre prax 4/2018

Pharmacotherapy of multiple sclerosis in light of the necessary costs associated with prescribing the indicated drug

Multiple sclerosis is a serious neurological disease with the potential to significantly interfere with the patient's daily activities. In recent years, there has been an unpredictable increase in the supply of medicines with innovative mechanisms of action that offer the chance to patients for the significantly longer sustained quality of life. However, their prescription also brings some additional costs in terms of the requirement for ongoing patient investigation / monitoring, etc. The aim of this article is to find out and de facto draw the differences in this area among the registered drugs of the individual treatment lines.

Keywords: multiple sclerosis, sclerosis multiplex, disability, costs